Entering text into the input field will update the search result below

FDA OKs Merck's Keytruda/Chemotherapy combo in triple-negative breast cancer

  • Merck (NYSE:MRK) announces that the FDA has approved KEYTRUDA, an anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery, based on

Recommended For You

About MRK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRK--
Merck & Co., Inc.